Blogs /
IPO Note / Manipal Health Enterprises Limited IPO Analysis: Comprehensive Deep Dive, Key Financials and Analyst Recommendation
By Sushil Finance
28 July 2026 • 8 MINUTES READ
Manipal Health Enterprises Limited IPO Analysis: Comprehensive Deep Dive, Key Financials and Analyst Recommendation
Key Highlights & Overview
Manipal Health Enterprises Limited is launching its ₹9,275.22 Cr IPO opening on July 29, 2026, and closing on July 31, 2026 with a price band of ₹560 to ₹590 per equity share (Face Value ₹2).
- Market Position: India's largest pan-India multispecialty hospital network by bed capacity operating 13,037 beds as of March 31, 2026, and second-largest by hospital count.
- Triple-Metro Moat: Only private hospital network with simultaneous market leadership in Bengaluru, Kolkata, and Pune.
- Financial Growth: Operational revenue scaled from ₹6,172 Cr in FY24 to ₹10,336 Cr in FY26 (29.41% CAGR). EBITDA rose from ₹1,596.98 Cr to ₹2,721.87 Cr (~26-29% margin band).
- Deleveraging Focus: Fresh issue of ₹800 Cr will primarily prepay/repay ₹552.76 Cr subsidiary debt and buy out minority stake in Sahyadri Hospitals (₹57.40 Cr), clearing non-recurring interest drag.
- Analyst Stance: Diluted FY26 EPS of ₹7.67 provides meaningful re-rating potential when compared to listed peer valuations (Apollo, Max, Fortis) trading at 66x-75x earnings.
1. IPO Overview
Manipal Health Enterprises Limited (operating under the widely recognized brand manipalhospitals) is tapping the primary capital market with a public issue of ₹9,275.22 Crore. The company stands as India's largest pan-India multispecialty healthcare provider by bed capacity and the second-largest hospital chain in the country by hospital footprint.
The offer opens on Wednesday, July 29, 2026, and closes on Friday, July 31, 2026. The price band has been fixed at ₹560 to ₹590 per share of face value ₹2 each. The company's equity shares will be listed on both major Indian stock exchanges, the BSE Limited and the National Stock Exchange of India Limited (NSE).
2. Key IPO Details
The total issue size of ₹9,275.22 Crore consists of a Fresh Issue of ₹800.00 Crore and an Offer For Sale (OFS) of ₹1,275.22 Crore by selling shareholders, amounting to a total of 15,72,07,054 equity shares.
Issue Details Summary Table
| Parameter |
Details |
| Price Band |
₹560 to ₹590 Per Share |
| Issue Opens On |
July 29, 2026 |
| Issue Closes On |
July 31, 2026 |
| Lot Size |
25 Shares & in Multiples thereafter |
| Face Value |
₹2 Per Share |
| Total Issue Size |
₹9275.22 Cr. (15,72,07,054 Equity Shares) |
| Listing On |
BSE & NSE |
Offer Structure Breakdown
| Issuance Component |
Amount (in ₹ Cr.) |
| Fresh Issue |
8000.00 |
| Offer For Sale (OFS) |
1275.22 |
| Total Issue Size |
9275.22 |
Category-wise Issue Reservation (At Upper Price Band)
| Reservation Category |
% of Issue Allocation |
Amount (in ₹ Cr. at Upper Band) |
| Qualified Institutional Buyers (QIB) |
75% |
6956.42 |
| Non-Institutional Investors (HNI) |
15% |
1391.28 |
| Retail Individual Investors (RETAIL) |
10% |
927.52 |
| TOTAL |
100% |
9275.22 |
Lead Managers & Intermediaries
Book Running Lead Managers (BRLMs):
- Kotak Mahindra Capital Co. Ltd.
- Axis Capital Ltd.
- Goldman Sachs (India) Securities Pvt. Ltd.
- Jefferies India Pvt. Ltd.
- JP Morgan India Pvt. Ltd.
- UBS Securities India Pvt. Ltd.
- DBS Bank India Ltd.
Registrar to the Offer: Kfin Technologies Ltd.
3. Company Overview
Manipal Health Enterprises Limited is India's largest pan-India multispecialty hospital network by bed capacity, operating 13,037 beds as of March 31, 2026. It represents the second-largest hospital chain in the country by overall hospital count.
The company's defining strategic feature is that it stands as the only private hospital chain in India with market leadership in three separate metro regions simultaneously: Bengaluru, Kolkata, and Pune. This provides a balanced metro and non-metro geographic mix across key population centers.
High-Acuity Clinical Capability & Economic Moat
Clinically, Manipal operates at the high-acuity end of healthcare provision. Its specialized capabilities include:
- Cardiology & Cardiac Surgery: Routine structural heart and minimally invasive cardiac surgeries.
- Organ Transplants: Comprehensive multi-organ transplant programs across liver, heart, and kidney.
- Neuro & Spine Care: Complex neuro and spine procedures, including advanced epilepsy surgery and deep brain stimulation (DBS).
- Oncology: Advanced oncology services including bone marrow transplantation (BMT) and precision oncology.
- Gastroenterology & Radiology: Advanced interventional radiology and complex gastroenterology procedures.
This high clinical intensity supports superior case-mix economics, translating to higher revenue per occupied bed and robust operating margins compared to secondary-care hospital networks. Replicating this depth of clinical specialization acts as a formidable competitive moat, as it requires intensive capital investments and top-tier doctor talent acquisition that new market entrants cannot easily replicate.
Patient-Centric & Digital Care Model
The company has established a protocol-driven, patient-centric care delivery framework. Underpinned by digital scheduling platforms, optimized turnaround times, and multi-lingual patient support systems, the brand manipalhospitals has emerged as a "network of choice" for patients, doctors, and healthcare professionals alike.
4. Objects of the Issue
The total Offer comprises a ₹800 Crore Fresh Issue along with an Offer for Sale of ₹1,275.22 Crore (the proceeds of which go directly to the selling shareholders and not to the company).
The net proceeds from the Fresh Issue will be deployed primarily toward strategic capital structure optimization:
- Subsidiary Debt Prepayment/Repayment: ₹552.76 Crore will be utilized to repay or prepay existing borrowings at its subsidiary, Manipal Hospitals Pvt Ltd.
- Minority Stake Buyout: ₹57.40 Crore will be deployed to buy out the minority stake in Sahyadri Hospitals Pvt Ltd.
- General Corporate Purposes: The balance fresh proceeds will be allocated toward general corporate functions.
Key Note: This capital raise is essentially a deleveraging + minority buyout issue rather than a growth-capex raise, which will directly reduce finance costs and eliminate debt overhang.
5. Key Highlights
- Pan-India Scale Leadership: India's largest multispecialty hospital network by bed capacity (13,037 beds) with established market leadership in three key metro regions.
- Unique Triple-Metro Presence: Only private hospital operator dominating Bengaluru, Kolkata, and Pune with a balanced metro/non-metro mix.
- Trusted Healthcare Brand: High brand recognition among patients and clinical talent, driven by transparent, digitally enabled, protocol-based care.
- Advanced Super-Specialty Capability: Comprehensive clinical infrastructure enabling complex high-acuity interventions (organ transplants, cardiac care, neuro/spine care, precision oncology).
- Industry-Leading Profitability Trajectory: Demonstrated strong financial performance with a 29.41% Revenue CAGR and a 31.11% PAT CAGR over the FY24–FY26 period.
6. Brief Financial Summary
Below is the detailed financial summary of Manipal Health Enterprises Limited for the fiscal years ended March 31, 2024, 2025, and 2026 (Figures in ₹ Crore, except EPS & RoNW):
| Particulars |
FY2024 (₹ Cr.) |
FY2025 (₹ Cr.) |
FY2026 (₹ Cr.) |
| Total Income |
6,265.17 |
8,362.79 |
10,520.52 |
| Total Expenditure |
5,340.51 |
7,134.43 |
9,268.42 |
| EBITDA |
1,596.98 |
2,261.02 |
2,721.87 |
| Profit Before Tax (PBT) |
745.04 |
1,242.31 |
1,178.03 |
| Profit After Tax (PAT) |
533.20 |
1,081.67 |
916.52 |
| EPS (Diluted in ₹) |
5.25 |
9.25 |
7.67 |
| Return on Net Worth (RONW %) |
14.75% |
18.16% |
10.57% |
* Note: Financial figures are non-annualized.
7. Bidding & Application Lot Size Charts
Retail Category Application Price Chart (@ ₹590 Upper Price Band)
| Lot Count |
No. of Shares |
Minimum Application Amount (₹) |
| 1 Lot | 25 | 14,750 |
| 2 Lots | 50 | 29,500 |
| 3 Lots | 75 | 44,250 |
| 4 Lots | 100 | 59,000 |
| 5 Lots | 125 | 73,750 |
| 6 Lots | 150 | 88,500 |
| 7 Lots | 175 | 1,03,250 |
| 8 Lots | 200 | 1,18,000 |
| 9 Lots | 225 | 1,32,750 |
| 10 Lots | 250 | 1,47,500 |
| 11 Lots | 275 | 1,62,250 |
| 12 Lots | 300 | 1,77,000 |
| 13 Lots | 325 | 1,91,750 |
High Net-Worth Individual (HNI) Application Chart
| HNI Category |
No. of Shares |
Minimum Bid Amount (₹) |
| Small HNI |
350 Shares |
2,06,500 |
| Big HNI |
1,700 Shares |
10,03,000 |
8. Indicative IPO Timeline
| Tentative Milestone Event |
Indicative Date |
| Issue Opening Date |
July 29, 2026 |
| Issue Closing Date |
July 31, 2026 |
| Finalisation of Basis of Allotment |
August 3, 2026 (03/08/2026) |
| Initiation of Refunds / Unblocking Funds |
August 4, 2026 (04/08/2026) |
| Credit of Equity Shares to Demat Accounts |
August 4, 2026 (04/08/2026) |
| Commencement of Trading on BSE & NSE |
August 5, 2026 (05/08/2026) |
9. Our View / Research Recommendation
Sushil Finance View
Strong Operational Scaling & Profitable Growth: Manipal's Revenue from operations nearly doubled from ₹6,172 Crore in FY24 to ₹10,336 Crore in FY26 (a robust 29.4% CAGR). Simultaneously, EBITDA grew from ₹1,597 Crore to ₹2,721 Crore, with operating margins holding steady in a healthy ~26-29% band throughout. This confirms that top-line growth has been highly profitable rather than merely volume-driven.
Contextualizing the FY26 PAT & RoNW Moderation: The FY26 dip in Profit After Tax (₹917 Crore vs ₹1,082 Crore in FY25) and the temporary compression in Return on Net Worth (RoNW falling from 18.2% to 10.6%) might appear concerning at first glance. However, these are largely explained by identifiable, non-recurring factors: a temporary swing in exceptional items and a step-up in finance costs tied directly to debt raised for acquiring Sahyadri Hospitals. Crucially, these exact borrowings are what the ₹800 Crore Fresh Issue is designed to prepay/repay.
Unmatched Moat & Re-Rating Opportunity: Combined with category leadership as India's largest hospital network by beds, unmatched dominance across three metro hubs, and a repeatable M&A integration playbook, Manipal presents a strong structural narrative. Listed peers like Apollo Hospitals, Max Healthcare, and Fortis Healthcare trade at rich multiples of 66x to 75x diluted earnings. In comparison, Manipal's diluted FY26 EPS of ₹7.67 offers meaningful valuation re-rating potential for long-term investors.
10. Frequently Asked Questions (FAQs)
Q1: What are the opening and closing dates for the Manipal Hospital IPO?
The IPO opens for public subscription on July 29, 2026, and closes on July 31, 2026.
Q2: What is the price band and minimum investment for retail investors?
The price band is ₹560 to ₹590 per share. The minimum lot size is 25 equity shares, requiring a minimum retail investment of ₹14,750 at the cut-off price of ₹590 per share.
Q3: How many beds does Manipal Health Enterprises operate?
As of March 31, 2026, Manipal operates 13,037 beds, making it the largest pan-India multispecialty hospital network by bed capacity.
Q4: What are the objects of the fresh issue?
The ₹800 Crore fresh proceeds will be used to prepay/repay ₹552.76 Crore borrowings at subsidiary Manipal Hospitals Pvt Ltd, ₹57.40 Crore to buy out the minority stake in Sahyadri Hospitals Pvt Ltd, and the remaining for general corporate purposes.
Q5: Who is the registrar for the Manipal Hospital IPO?
Kfin Technologies Ltd is the official registrar for the issue.
DISCLAIMER
The content provided in this blog is for informational and educational purposes only and should not be construed as investment, legal, or tax advice. While Sushil Finance makes reasonable efforts to ensure accuracy and reliability of the information, we do not guarantee its completeness or timeliness. Readers are advised to consult with their financial advisor before making any investment decisions. Sushil Finance shall not be held responsible for any direct or indirect loss arising from use of this content. Investments in securities are subject to market risks. Read all scheme-related documents carefully before investing.
